Skip to main content

Transgenomic EGFR C797S Mutation Detection Assay

Transgenomic has launched its EGFR C797S Mutation Detection assay. The assay is based on the company's ICE COLD-PCR technology and detects the presence of the EGFR C797S mutation that is associated with resistance to new third-generation tyrosine kinase inhibitor therapies in development for non-small cell lung cancer. The high sensitivity of Transgenomic's ICP technology makes it possible to run the new assay using either tissue, blood, or serum samples, the company said. The test is currently only available for research use through Transgenomic's Biomarker Discovery Services group, and is expected to be available for clinical use through the company's oncology CLIA laboratory in Omaha, Nebraska later this year.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.